Michael Krämer

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig et al. · Blood Cancer Journal · 2014 · 344 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Immunotherapy +17

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

Hannes Wandt, Kerstin Schaefer‐Eckart, Knut Wendelin et al. · The Lancet · 2012 · 335 citations

Thrombosis, Blood Platelet, Therapeutic Platelet Transfusion +10

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

Utz Krug, Christoph Röllig, Anja Koschmieder et al. · The Lancet · 2010 · 302 citations

Hematological Malignancy, Prognostic Evaluation, Medicine +12